CombiMatrix Corp. (CBMX) Enters Strategic Partnership With Manhattan Labs

Aug. 13, 2013 1:54 PM ETCBMX
MissionIR profile picture
MissionIR's Blog
133 Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Small cap

Contributor Since 2010

We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to building shareholder value. View our website at www.MissionIR.com MissionIR provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.missionir.com.

CombiMatrix is a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques including microarray, standardized, and customized FISH, and high resolution karyotyping.

The company today announced a strategic partnership with Manhattan Labs, an independent clinical laboratory that serves the New York City area. Its emphasis is on women's health, particularly obstetrics and reproductive issues. Manhattan labs will market and distribute in New York City CombiMatrix microarray tests for the miscarriage management testing market.

The agreement between the two firms was directly enabled by the announcement in June that CombiMatrix miscarriage management tests had received conditional approval from the New York State Department of Health for testing on patient samples within New York state.

Miscarriage management testing allows OB/GYN doctors to better determine if there is a genetic cause for a miscarriage or other related events. Microarray testing is believed by many in the industry to be the coming standard of care since it can identify a greater number of possible genetic abnormalities more accurately than currently available technology.

The partnership is a key step for CombiMatrix. First, it shows that microarray testing is indeed becoming more and more accepted as a diagnostic tool in the women's health field. Secondly, it gives the company access into the large New York City market for its leading growth product. For additional information about CombiMatrix and its entire product line, please visit combimatrix.com.

Please see disclaimer on the MissionIR website

www.missionir.com/disclaimer.html

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.